摘要
断裂检查站和拓扑异构酶II(ToPoII)之间的相互作用是维持基因组完整性至关重要的因素。这种酶的靶向药物已经在癌症治疗的临床应用超过30年,并取得了巨大的成功。已开发的拓扑异构酶II化合物的种类大致分为毒素和催化抑制剂。拓扑异构酶II毒素是一种在临床使用中和常见的化疗药物一样,对正常组织有相当大的毒性抗癌疗法。拓扑异构酶II亚型已经涉及到这种细胞毒性。拓扑异构酶II活性由几种因素决定,其中细胞周期检查点在其敏感性和抑制性方面起着重要的作用。在考虑这些药物的有效性方面,G2/M期检查点尤为重要,本文对此进行了综述。ATM依赖的断裂检查点功能性可能是代表选择癌症治疗的新途径。在这里,我们综述拓扑异构酶II的功能、抗癌机制及目前的催化抑制剂和毒素的局限性以及它们对细胞周期检查点的影响。我们也将探讨这种靶向酶限制正常组织毒性的可能的机制,以及如何由这些药物触发的细胞周期检查点提供一种替代方法和更好的治疗靶点。
关键词: 拓扑异构酶Ⅱ,细胞周期检查点,基因组完整性,细胞毒性,G2/M相检查点,拓扑异构酶Ⅱ毒素
Current Medicinal Chemistry
Title:Topoisomerase II Inhibitors and Poisons, and the Influence of Cell Cycle Checkpoints
Volume: 24 Issue: 15
关键词: 拓扑异构酶Ⅱ,细胞周期检查点,基因组完整性,细胞毒性,G2/M相检查点,拓扑异构酶Ⅱ毒素
摘要: Interactions between the decatenation checkpoint and Topoisomerase II (TopoII) are vital for maintaining integrity of the genome. Agents that target this enzyme have been in clinical use in cancer therapy for over 30 years with great success. The types of compounds that have been developed to target TopoII are broadly divided into poisons and catalytic inhibitors. The TopoII poisons are in clinical use as anti-cancer therapies, although in common to most chemotherapeutic agents, they display considerable normal tissue toxicity. Inhibition of the TopoIIb isoform has been implicated in this cytotoxicity. Response to TopoII active agents is determined by several factors, but cell cycle checkpoints play a large role in sensitivity and resistance. The G2/M phase checkpoints are of particular importance in considering the effectiveness of these drugs and are reviewed in this article. Functionality of the ATM dependent decatenation checkpoint may represent a new avenue for selective cancer therapy. Here we review the function of TopoII, the anti-cancer mechanisms and limitations of current catalytic inhibitors and poisons, and their influence on cell cycle checkpoints. We will also assess potential new mechanisms for targeting this enzyme to limit normal tissue toxicity, and how the cell cycle checkpoint triggered by these drugs may provide an alternative and possibly better target for novel therapies.
Export Options
About this article
Cite this article as:
Topoisomerase II Inhibitors and Poisons, and the Influence of Cell Cycle Checkpoints, Current Medicinal Chemistry 2017; 24 (15) . https://dx.doi.org/10.2174/0929867323666161205122613
DOI https://dx.doi.org/10.2174/0929867323666161205122613 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antimicrobial Activity of New 2-Thioxo-benzo[g]quinazolin-4(3H)-one Derivatives
Medicinal Chemistry Talazoparib Loaded Solid Lipid Nanoparticles: Preparation, Characterization and Evaluation of the Therapeutic Efficacy In vitro
Current Drug Delivery The Urokinase-type Plasminogen Activator and the Generation of Inhibitors of Urokinase Activity and Signaling
Current Pharmaceutical Design Interleukin-24: A Molecule with Potential Anti-Cancer Activity and a Cytokine in Search of a Function
Endocrine, Metabolic & Immune Disorders - Drug Targets Production, Novel Assay Development and Clinical Applications of Monoclonal Antibodies
Recent Patents on Anti-Cancer Drug Discovery Effect of Number of Bifunctional Chelating Agents on the Pharmacokinetics and Immunoreactivity of 177Lu-labeled Rituximab: A Systemic Study
Anti-Cancer Agents in Medicinal Chemistry A Mechanistic Overview on Male Infertility and Germ Cell Cancers
Current Pharmaceutical Design Novel Drug Therapies for Fertility Preservation in Men Undergoing Chemotherapy: Clinical Relevance of Protector Agents
Current Medicinal Chemistry From the Table to the Bedside: Can Food-Derived Sulforaphane be used as a Novel Agent to Treat Leukemia?
Current Cancer Drug Targets De Novo Design of New Inhibitor of Mutated Tyrosine-Kinase for the Myeloid Leukemia Treatment
Current Pharmaceutical Design Improving the Targeting of Tubulin-Binding Agents: Lessons from Drug Resistance Studies
Current Pharmaceutical Design Potential Beneficial Effects of Garlic in Oncohematology
Mini-Reviews in Medicinal Chemistry Autophagy Driven Extracellular Vesicles in the Leukaemic Microenvironment
Current Cancer Drug Targets Molecular Dynamics and Structural Studies of the Ets Domain-DNA Complexes
Current Bioinformatics Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes
Current Pharmaceutical Design Basis for Resistance to Imatinib in 16 BCR-ABL Mutants as Determined Using Molecular Dynamics
Recent Patents on Anti-Cancer Drug Discovery A Brief Review of the Essential Role of Nanovehicles for Improving the Therapeutic Efficacy of Pharmacological Agents Against Tumours
Current Drug Delivery Recent Patents in Antiviral siRNAs
Recent Patents on Anti-Infective Drug Discovery Contrast Enhanced Sonography for Diagnosis of (Peri-) Splenic Pathology
Current Medical Imaging New Approaches With Natural Product Drugs for Overcoming Multidrug Resistance in Cancer
Current Pharmaceutical Design